[go: up one dir, main page]

PE20120331A1 - Agentes medicinales unidos a dipeptido - Google Patents

Agentes medicinales unidos a dipeptido

Info

Publication number
PE20120331A1
PE20120331A1 PE2011001237A PE2011001237A PE20120331A1 PE 20120331 A1 PE20120331 A1 PE 20120331A1 PE 2011001237 A PE2011001237 A PE 2011001237A PE 2011001237 A PE2011001237 A PE 2011001237A PE 20120331 A1 PE20120331 A1 PE 20120331A1
Authority
PE
Peru
Prior art keywords
alkyl
group
dipeptide
medicinal agent
breaking
Prior art date
Application number
PE2011001237A
Other languages
English (en)
Inventor
Richard D Dimarchi
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of PE20120331A1 publication Critical patent/PE20120331A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPLEJO QUE COMPRENDE: (I) UN GRUPO DIPEPTIDO DE AUTO ROTURA NO ENZIMATICA DE ESTRUCTURA GENERAL (A-B) DONDE: A ES UN AMINOACIDO O HIDROXIL ACIDO; B ES UN AMINOACIDO N-ALQUILADO; (II) UN AGENTE MEDICINAL (Q) TAL COMO UN PEPTIDO BIOACTIVO QUE ESTA UNIDO COVALENTEMENTE AL GRUPO DE AUTO ROTURA; EN DONDE EL GRUPO DE AUTO ROTURA ESTA UNIDO A DICHO AGENTE MEDICINAL A TRAVES DE UN ENLACE DE AMIDA ENTRE B Y UNA AMIDA DEL AGENTE MEDICINAL; (III) UN POLIMERO DE DEPOSITO TAL COMO POLIETILENGLICOL QUE TIENE UN PESO MOLECULAR ENTRE 40.000 A 80.000 QUE ESTA UNIDO A LA CADENA LATERAL A O B A TRAVES DE UNA UNION A UN GRUPO ACILO O GRUPO ALQUILO C16-C18. EL GRUPO DIPEPTIDO COMPRENDE LA ESTRURA DE FORMULA (i) DONDE: R1, R2, R4 Y R8 SE SELECCIONAN INDEPENDIENTEMENTE DE H, ALQUILO C1-C18, ALQUENILO C2-C18, (ALQUILO C1-C18)OH, (ALQUILO C1-C18)SH, ENTRE OTROS; R3 ES ALQUILO C1-C18, (ALQUILO C1-C18)NH2, (ALQUILO C0-C4)CICLOALQUILO C3-C6, (ALQUILO C0-C4)(HETEROCICLICO C2-C5), ENTRE OTROS. DICHO COMPLEJO MEJORA LA SOLUBILIDAD, ESTABILIDAD Y/O FARMACOCINETICA DEL PROFARMACO
PE2011001237A 2008-12-19 2009-12-18 Agentes medicinales unidos a dipeptido PE20120331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13922708P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
PE20120331A1 true PE20120331A1 (es) 2012-04-14

Family

ID=42316744

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001237A PE20120331A1 (es) 2008-12-19 2009-12-18 Agentes medicinales unidos a dipeptido

Country Status (13)

Country Link
US (1) US20110237493A1 (es)
EP (1) EP2376098A4 (es)
JP (2) JP2012512898A (es)
KR (1) KR20110114568A (es)
CN (1) CN102300580A (es)
AU (1) AU2009335711A1 (es)
CA (1) CA2747195A1 (es)
IL (1) IL213341A0 (es)
MX (1) MX2011006527A (es)
PE (1) PE20120331A1 (es)
RU (1) RU2578591C2 (es)
SG (1) SG172290A1 (es)
WO (1) WO2010080605A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
US8981047B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Glucagon antagonists
CN101983066B (zh) 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
BRPI0915282A2 (pt) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
KR20110039230A (ko) 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
PE20120914A1 (es) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES WITH G-PROTEIN-COUPLED RECEPTOR ACTIVITY
CN103079587B (zh) 2010-05-13 2016-05-11 印第安纳大学研究及科技有限公司 呈现核激素受体活性的胰高血糖素超家族肽
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
WO2011163462A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
RU2013102991A (ru) * 2010-06-24 2014-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Связанные с дипептидом лекарственные средства
KR20130132931A (ko) 2010-12-22 2013-12-05 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체 활성을 나타내는 글루카곤 유사체들
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
KR101972617B1 (ko) 2011-06-22 2019-04-25 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-항진제들
BR112014007124A2 (pt) * 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
EP2793932B1 (en) 2011-12-20 2018-10-03 Indiana University Research and Technology Corporation Ctp-based insulin analogs for treatment of diabetes
CN103172726B (zh) * 2011-12-22 2017-06-13 杭州淳泰科技有限公司 胰泌素类似物及其制备方法和用途
JP6300735B2 (ja) 2012-03-01 2018-03-28 ノヴォ ノルディスク アー／エス Ｇｌｐ−１プロドラッグ
ES2602486T3 (es) 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
CN105934257B (zh) 2013-12-06 2020-10-09 韩捷 用于含氮和羟基的药物的生物可逆引入基团
CN107001441A (zh) 2014-09-24 2017-08-01 印第安纳大学研究及科技有限公司 脂质化的基于酰胺的胰岛素前药
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
CN116731101A (zh) 2016-06-01 2023-09-12 雅斯娜 用于治疗多种疾病的n-己酸-l-酪氨酸-l-异亮氨酸-(6)-氨基己酰胺的衍生物
JP2023527356A (ja) * 2020-05-26 2023-06-28 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 副甲状腺機能低下症を処置するためのｐｔｈ類似体
WO2022018186A1 (en) 2020-07-22 2022-01-27 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
MX2023004672A (es) 2020-11-06 2023-07-20 Novo Nordisk As Profármacos de péptido tipo glucagón humano 1 (glp-1) y usos de los mismos.
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
JP2025517672A (ja) 2022-05-10 2025-06-10 ノヴォ ノルディスク アー／エス プロドラッグおよびその使用
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740385A (en) * 1970-05-07 1973-06-19 M Ondetti N-terminal derivatives of secretin
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
US4741897A (en) * 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
PT1171465E (pt) * 1999-03-29 2004-12-31 Uutech Ltd Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
AUPQ661800A0 (en) * 2000-03-31 2000-05-04 Metabolic Pharmaceuticals Limited Insulin-potentiating compounds
US6967202B2 (en) * 2000-08-04 2005-11-22 Dmi Biosciences, Inc. Method of synthesizing diketopiperazines
AU2001296962A1 (en) * 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
EP1243276A1 (en) * 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP2128246B1 (en) * 2001-04-19 2014-03-12 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-Aminoacyl-tRNA synthetase pairs
JP2005508895A (ja) * 2001-08-28 2005-04-07 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１および基礎インスリンの予備混合物
US7238656B2 (en) * 2001-08-29 2007-07-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
CZ2004710A3 (cs) * 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
FR2842209B1 (fr) * 2002-07-09 2007-11-23 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
HRP20050683A2 (en) * 2003-03-19 2006-07-31 Eli Lilly And Company Polyethylene glycol linked glp-1 compounds
CA2843439A1 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20070203058A1 (en) * 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
US20050187147A1 (en) * 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP1929030A2 (en) * 2005-09-08 2008-06-11 Shire LLC Prodrugs of t3 and t4 with enhanced bioavailability
CN101432025B (zh) * 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
MX2009002523A (es) * 2006-09-08 2009-03-20 Ambrx Inc Polipeptido de plasma humano modificado o andamios fc y sus usos.
DE102006052755A1 (de) * 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh Michaelsysteme als Transglutaminaseinhibitoren
MX2009008241A (es) * 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
CN101983066B (zh) * 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
SG172291A1 (en) * 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs

Also Published As

Publication number Publication date
US20110237493A1 (en) 2011-09-29
JP2012512898A (ja) 2012-06-07
SG172290A1 (en) 2011-07-28
RU2578591C2 (ru) 2016-03-27
AU2009335711A1 (en) 2010-07-15
CN102300580A (zh) 2011-12-28
MX2011006527A (es) 2011-08-17
IL213341A0 (en) 2011-07-31
WO2010080605A1 (en) 2010-07-15
RU2011129764A (ru) 2013-01-27
EP2376098A4 (en) 2014-06-11
KR20110114568A (ko) 2011-10-19
CA2747195A1 (en) 2010-07-15
EP2376098A1 (en) 2011-10-19
JP2016028082A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
PE20120331A1 (es) Agentes medicinales unidos a dipeptido
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20091575A1 (es) Derivados bifenilo como inhibidores del virus de la hepatitis c
ECSP099638A (es) Nuevo compuesto de adenina
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
TN2012000125A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
ES2567418T3 (es) Derivados citotóxicos de benzodiazepina
PE20130579A1 (es) Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
PE20091783A1 (es) Anticuerpos anti-factor d humanizados
SV2008002969A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
DOP2010000046A (es) Compuestos de biciclolactama sustituida
PH12012501881A1 (en) 4-amino-4- oxobutanoyl peptides as inhibitors of viral replication
PE20090226A1 (es) PIRROLIDINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa Y SU PREPARACION
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
PE20081834A1 (es) Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
AR066103A1 (es) Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
PE20090618A1 (es) Compuestos para el tratamiento de hepatitis c
PE20070171A1 (es) GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
PE20080364A1 (es) Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa
AU2005265164A2 (en) Non-natural amino acids
PE20081261A1 (es) DERIVADOS DEL FLUORENO COMO INHIBIDORES DE LA PROTEINA CHAPERONA Hsp90 Y COMPOSICIONES QUE LOS CONTIENEN

Legal Events

Date Code Title Description
FC Refusal